Sticky post

Tetra Bio-Pharma first-past-the-post on clinical trial for chronic pain

Tetra Bio-Pharma and clinical research partner Santé Cannabis conduct first-ever and most exhaustive clinical trial to evaluate safety and efficacy of different doses and ratios of cannabis oils versus placebo for (non-cancer) chronic pain. On track for completion later this fall.
Continue reading Tetra Bio-Pharma first-past-the-post on clinical trial for chronic pain

Health Canada makes Tetra Bio-Pharma cannabis-delivery product a Class Two medical device.

Heath Canada decision to reclassify, to a Phase Two medical device, the @TetraBioPharma inhalation pipe for cannabis medication means that patients suffering cancer pain may soon be able to claim the cost through their private and public insurance plans. Continue reading Health Canada makes Tetra Bio-Pharma cannabis-delivery product a Class Two medical device.

Sticky post

Aphria signs deal; exclusive global partner for QuickStrip

Aphria and Canadian bio-technology company Rapid Dose Therapeutics have signed an MOU that Aphria will have exclusive global preferred rights to produce, distribute and sell QuickStrip(TM) products for cannabis markets around the world, once a definitive agreement is signed between the two companies in the near future. Continue reading Aphria signs deal; exclusive global partner for QuickStrip

Sticky post

“Old” cannabis-plant research finally sees the light of day, as the stigma of cannabis slowly melts away

The potential healing properties of cannabis are becoming increasingly evident. Hundreds of thousands of studies have been done in search of better treatment for diseases involving just about every system and organ in the body.
Continue reading “Old” cannabis-plant research finally sees the light of day, as the stigma of cannabis slowly melts away